Sign in
Taking people in South KoreaNo phase

Tests a scan to guide adrenal surgery in primary aldosteronism

Tests a gallium-68 pentixafor PET scan in adults with primary aldosteronism.

Key facts

Who runs it
Seoul National University Hospital
Where
Seoul, South KoreaSee the 2 sites
Trial code
Registry title
PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
Status
Recruiting
People taking part
90 people, planned
Started
25 Jun 2025
Expected to end
1 Dec 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • 68Ga-pentixafor PET/CT
Record updated
18 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary aldosteronism (too much of the hormone aldosterone) who had an adrenal CT scan. It tests whether an added PET/CT scan improves surgery results.

Age
19 years or older
Sex
All sexes can join.
Disease stage
Primary aldosteronism diagnosed under the 2016 Endocrine Society guidelines.
Earlier treatment
An adrenal CT scan must have been done. People with earlier open abdominal surgery or retroperitoneal surgery on the same side as the planned adrenalectomy cannot join.

Main reasons for not taking part

  • Pregnant or breastfeeding women, or women who may become pregnant
  • People who refuse to have surgery
  • People who cannot have, or refuse, the 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT or adrenal venous sampling (AVS)
  • People who refuse or react badly to the dexamethasone needed before the 11C-Metomidate PET/CT
  • Earlier open abdominal or retroperitoneal surgery on the same side as the planned adrenalectomy

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age ≥19 years
  • Diagnosed with PA per 2016 Endocrine Society guidelines
  • Underwent adrenal CT
  • Signed informed consent

Who cannot take part

  • Individuals who refuse to undergo surgery
  • Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT
  • Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions
  • Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy
  • Women who are pregnant, breastfeeding, or may become pregnant
  • Any individual deemed unsuitable for the study at the discretion of the investigator

Where in South Korea

  • Samsung Medical CenterSeoul, South KoreaContact: You bin Lee, M.D, Ph.DTaking people
  • Seoul National University HospitalSeoul, South KoreaContact: Seungho Lee, M.DTaking people

About the trial

What the trial wants to find out

This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.

The 2 groups in the trial

  • AVS + 68Ga-pentixafor PET/CT (+ 11C-metomidate PET/CT)Treatment being tested

    Intervention: Diagnostic Imaging: 68Ga-pentixafor PET/CT With 68Ga-pentixafor PET/CT imaging added to AVS for lateralization Subset only: 11C-metomidate PET/CT (for research use only, not used in treatment decisions)

    Treatment: 68Ga-pentixafor PET/CT

  • AVS onlyNo study treatment, for comparison

    No PET/CT Without 68Ga-pentixafor PET/CT imaging; AVS only (Gold standard)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)
Plain-language title
Tests a scan to guide adrenal surgery in primary aldosteronismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 June 2025